Prelude Therapeutics Incorporated (PRLD)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Prelude (PRLD) announces major capital raise selling shares and warrants
# 📜 What This Document Is ✨ This document is an 8-K filing, which is a very important, mandatory filing used to announce major, unexpected events that happen *after* the company has already been publicly listed. Think of it like an urgent "Heads Up!" bulletin to investors. In simple terms, Prelud
PRLD shows promising preclinical data; aims for 2026 IND filing
# 📑 What This Document Is 📄 This filing is a material disclosure (an 8-K) announcing significant scientific progress for Prelude Therapeutics. It serves to update investors and the public on the impressive preclinical data generated for the company's lead drug candidate, PRT13722. 👉 Essentially,
SEC filings
All filings →Insider trades
All insider trades →Prelude Therapeutics Incorporated has no reported insider trades in the last 90 days.